In order to target YTHDF1 in vivo, Lin et al. developed a system for exosome-mediated CRISPR/Cas9 delivery, which leads to YTHDF1 depletion and restores tumor immune surveillance [78]. Here, YTHDF1 is linked to neoplasm.